Table 2.

Changes of Morphology and Function over time in Hypertrophic Cardiomyopathy. The study cohort presented with a significant gain of left ventricular mass, fibrosis and left atrial volume after a mean follow up duration of 5.2 ± 2.4 years. These findings were accompanied by a decrease of left and right ventricular ejection fraction and an impact on NYHA functional class.

Parameter (n = 32)	Baseline	Follow Up	Δchange	p
Heart rate [bpm]	60 ± 8	62 ± 10		n.s.
NYHA class	1 (1–1)	1 (1–2)	+ 0.3	0.02
hs-TNT [ng/l]	11 ± 8	19 ± 11		n.s.
NT-proBNP [ng/l]	861 ± 1332	563 ± 720		n.s.
LV septal wall thickness [mm]	18 ± 4	19 ± 4	+ 1.0	0.01
LV posterior wall thickness [mm]	8 ± 3	9 ± 3	+ 0.8	0.02
LV Mass [gr]	194 ± 56	217 ± 60	+ 23	0.0001
LV papillary muscle mass [gr]	4 ± 2	5 ± 2	+ 0.9	0.03
LVEDV [ml]	156 ± 36	152 ± 34		n.s.
LVESV [ml]	46 ± 14	51 ± 16		n.s.
LVEF [%]	70 ± 9	66 ± 9	− 3.7	0.04
MAPSE [mm]	11 ± 3	12 ± 3		n.s.
LA volume [ml]	109 ± 41	129 ± 40	+ 20	0.0001
LGE mass [gr]	6.0 ± 17	7.8 ± 18	+ 1.8	0.006
RVEDV [ml]	152 ± 42	146 ± 42		n.s.
RVESV [ml]	47 ± 20	49 ± 21		n.s.
RVEF [%]	70 ± 7	67 ± 9	− 3.2	0.02
TAPSE [mm]	22 ± 5	22 ± 5		n.s.

Values are presented as mean ± standard deviation or median with interquartile range.

NYHA class = New York Heart Association functional class; hs-TNT = high sensitive Troponin T; NT-proBNP = N-terminal pro brain natriuretic peptide; LV = left ventricle; LVEDV/LVESV = left ventricular enddiastolic/ −systolic volume; LVEF = left ventricular ejection fraction; MAPSE = mitral annular plane systolic excursion; LA = left atrium; LGE = late gadolinium enhancement; RVEDV/RVESV = right ventricular enddiastolic/ −systolic volume; RVEF = right ventricular ejection fraction; TAPSE = tricuspid annular plane systolic excursion.